InvestorsHub Logo
Followers 27
Posts 398
Boards Moderated 0
Alias Born 12/10/2015

Re: None

Friday, 10/14/2022 1:02:44 PM

Friday, October 14, 2022 1:02:44 PM

Post# of 471186
Dec 1 at 4:30pm: LB8 - Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer’s Disease

(AD) Stephen Macfarlane 1, Timo Grimmer 2, Terence O’brien 3, Edward Hammond 4, Walter Kaufmann 4, Emmanuel Fadiran 4, Christopher Missling 4 1Hammoncare - Melbourne (Australia), 2THU Munich - Munich (Germany), 3Monash University, Alfred Health - Melbourne (Australia), 4Anavex Life

https://www.ctad-alzheimer.com/final-program
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News